YS Biopharma (NASDAQ:YSB) & Reviva Pharmaceuticals (NASDAQ:RVPH) Head to Head Analysis

Reviva Pharmaceuticals (NASDAQ:RVPH) and YS Biopharma (NASDAQ:YSB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 52.6% of YS Biopharma shares are held by institutional investors. 31.8% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Reviva Pharmaceuticals and YS Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	0	1	2	1	3.00
YS Biopharma	0	0	1	0	3.00

Reviva Pharmaceuticals currently has a consensus price target of $15.50, suggesting a potential upside of 1,241.99%. YS Biopharma has a consensus price target of $5.25, suggesting a potential upside of ∞. Given YS Biopharma’s higher probable upside, analysts plainly believe YS Biopharma is more favorable than Reviva Pharmaceuticals.

Profitability

This table compares Reviva Pharmaceuticals and YS Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	N/A	-280.50%
YS Biopharma	N/A	N/A	N/A

Volatility & Risk

Reviva Pharmaceuticals has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, YS Biopharma has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Earnings & Valuation

This table compares Reviva Pharmaceuticals and YS Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$39.26 million	($1.30)	-0.89
YS Biopharma	$560.76 million	0.00	-$21.17 million	N/A	N/A

YS Biopharma has higher revenue and earnings than Reviva Pharmaceuticals.

Summary

YS Biopharma beats Reviva Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

About YS Biopharma

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.